Navigation Links
Secretropin(R) - Effective, Preferable, Affordable as an Alternative to Injectable Growth Hormone - Gains Momentum
Date:2/2/2009

ENCINO, Calif., Feb. 2 /PRNewswire/ -- Secretropin(R), the first clinically proven natural stimulator of growth hormone production, is gaining the medical community's acceptance as a more desirable "first step" approach to pursuing hormonal balance. Although classified as a natural food supplement, Secretropin(R) is only available through a prescribing physician due to its clinically proven ability to increase the body's own production and release of growth hormone. This reproducible response of Secretropin's(R) use is reflected in its recently posted 9-month retail sales record of $1M.

Developed in 2001, Secretropin(R) received early medical acknowledgement for 2 key reasons: one, its reproducible effectiveness; and two, its preferable oral delivery. In as little as 4 weeks Secretropin(R) has been shown to increase the production of growth hormone by 50 - 200% while being delivered as an oral spray. Secretropin's(R) oral delivery system (ODS) owes its effectiveness to the latest nanoliposomal technology, which wraps the active agents in a protective envelop. Until this delivery technology was available, stomach acid would inactivate and destroy the active agents responsible for the increase in growth hormone production.

Prior to Secretropin(R), this left injectable growth hormone as the only other viable option. Fortunately, the nanoliposomal technology protects the complex, allowing for optimal absorption and leading to a more natural increase in growth hormone levels - thus eliminating the less desirable approach of daily injections.

On the financial side, the present global market for injectable human growth hormone (HGH) therapy is estimated to exceed $3B. The market is growing at a projected 15 to 20% rate as the world medical community recognizes the benefits to maintaining healthy hormone levels throughout life. Currently, injectable GH therapy costs approximately $1000/month, and with the technological advances captured by Secretropin(R), the cost range has been significantly reduced to between $150 and $200/month.

The Millennium Health Center, Inc. participated in the development of Secretropin(R) and provides ongoing clinical research (report). As of October 2006, there are over 3000 patient months of data being compiled by a number of independent centers throughout the U.S., Australia, New Zealand, India, Russia, Thailand, China, and Dubai. So far, Secretropin's(R) ability to increase growth hormone production has been reported in excess of 95% of the cases.

The combination of known benefits of healthy levels of human growth hormone, plus Secretropin's(R) clinically documented response rate, added to its cost-effectiveness, is what is being labeled as a responsible first-step approach to pursuing age-appropriate hormonal balanced therapy.

    For additional information:

    Mark L. Gordon, M.D.
    Millennium Health Centers, Inc.
    Email: Info@secretropinrx.com

Website: http://www.secretropinrx.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Millennium Health Centers, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
2. ZhenSpa.com provides Spa Enthusiasts Affordable Alternatives for Expensive Spa Treatments
3. DNA 11, Creators of DNA Art, Introduces a More Affordable Line of Custom Portraits for this Year's Gift Giving Season
4. BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices
5. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
6. XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
7. XTENT to Retain Investment Bank to Pursue Strategic Alternatives
8. N-Viro Fuel Technology Receives Alternative Energy Status From the U.S. Environmental Protection Agency
9. New uses for imidazolium salts in medicine and alternative energy
10. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
11. CPC of America, Inc. to Explore Strategic Alternatives; Appoints FTI Capital Advisors to Assess Potential Opportunities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), ... , today announced that its board of directors has amended its ... from March 27, 2017 to March 27, 2018. The amendment was not ... Biotech Ltd. ... Sinovac Biotech Ltd. is a China -based ...
(Date:3/23/2017)... ... 23, 2017 , ... AxioMed president, Jake Lubinski, describes the ... when deformed, which is identical to how the human discs work to distribute ... return to its natural state along a hysteresis curve, exactly like a healthy ...
(Date:3/23/2017)... 2017  SeraCare Life Sciences, Inc., a manufacturer ... diagnostics manufacturers and clinical laboratories, is announcing ... Inherited Cancer reference material for ... sequencing (NGS). The Seraseqâ„¢ Inherited Cancer DNA Mix ... industry experts to validate the ability of ...
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
Breaking Biology Technology:
(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
(Date:2/26/2017)... 25, 2017  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announces the ... "Too often, too many offenders return ... jails are trying to tackle this ongoing problem ... and family members. While significant steps are underway, Securus ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017  IBM ... Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, Home ... that will apply the power of IBM cognitive computing ... health centers. By analyzing data streaming from sensors in ... physical and environmental conditions, and obtain deeper learnings into ...
Breaking Biology News(10 mins):